Maryland Targets Drug Costs: New Upper Payment Limits for Ozempic

Maryland is taking significant steps to address the rising costs of prescription medications. The Maryland Prescription Drug Affordability Board has officially moved to establish an upper payment limit for Ozempic, a widely used treatment for type 2 diabetes. This decision marks a notable shift in how the state manages pharmaceutical expenditures for its residents and government entities.

Understanding the New Payment Caps

The board, which operates with a structure similar to a state utility commission, is implementing a strategy to curb the costs of specific high-cost drugs. By January 2027, the price of Ozempic will be capped at $274 for a 30-day supply for state and local government health plans. The board anticipates that this measure will result in approximately $5.8 million in annual savings.

According to Andrew York, executive director of the Maryland Prescription Drug Affordability Board, the decision to set this specific price point was benchmarked against the maximum fair price currently paid by Medicare. This alignment is intended to ensure that the cost-saving measures remain grounded in existing federal pricing standards.

Looking Ahead: Commercial Insurance Market

While the current action focuses on government-funded health plans, the state’s efforts are expected to expand. The board is preparing to begin a process in 2028 to set upper payment limits on high-cost drugs purchased by all Marylanders within the commercial insurance market. This broader application aims to extend relief to a larger segment of the population, addressing the financial burden of expensive specialty medications.

Key Takeaways

• Targeted Pricing: The state is capping the cost of Ozempic at $274 per 30-day supply starting in 2027.
• Government Savings: These measures are projected to save state and local governments $5.8 million annually.
• Future Expansion: Starting in 2028, the board plans to extend these upper payment limits to the broader commercial insurance market.
• Strategic Benchmarking: Price limits are being established using Medicare’s maximum fair price as a primary reference point.

Frequently Asked Questions

What is the Maryland Prescription Drug Affordability Board?

The board is a state-level regulatory body designed to function similarly to a utility commission. Its primary mandate is to oversee and manage the costs of prescription drugs to ensure they remain affordable for the state, local governments, and eventually, the general public.

How are these price limits determined?

The board evaluates high-cost drugs and benchmarks potential upper payment limits against existing federal standards, such as the maximum fair prices established by Medicare, to ensure the caps are reasonable and evidence-based.

When will these changes affect private insurance?

While initial caps are focused on government and local health plans by 2027, the board is scheduled to begin the process of setting limits for the commercial insurance market in 2028.

Disclaimer: This article is for informational purposes and does not constitute medical or financial advice. Patients should consult with their healthcare providers regarding their specific treatment plans and medication coverage.